← Back to Clinical Trials
Recruiting NCT02156401

NCT02156401 VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02156401
Status Recruiting
Phase
Sponsor Johannes Gutenberg University Mainz
Condition Venous Thromboembolism (VTE)
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2013-04
Primary Completion 2030-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2013-04 with a primary completion date of 2030-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Venous thromboembolism (VTE) with its two clinical manifestations deep vein thrombosis (DVT) and pulmonary embolism (PE) is a life-threatening disease that is associated with considerable morbidity and mortality. The incidence of VTE increases with age and it - as the third most common cardiovascular disease after ischemic heart disease and stroke - represents an important public health problem in industrialized countries with several aspects in need to be addressed. VTEval Project includes three long-term prospective observational studies to evaluate and improve VTE diagnostics and management, treatment and outcome. The aims of the project include a systematic assessment of VTE, i.e. disease status (symptoms, clinical and subclinical aspects) and risk profiles (classic, psychosocial and environmental factors), using a system-oriented approach. VTEval collects three large prospective cohorts of patients with suspected and incident VTE consisting of individuals with a clinical suspicion of acute PE, individuals with a clinical suspicion of acute DVT, and individuals with incidental diagnosis of VTE). The standardized and harmonized data acquisition of the study establishes a sustainable resource for comprehensive research on VTE, thus providing the basis for both short- and long-term analysis.

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years and Informed written consent * Clinical condition: * Cohort 1: Clinical suspicion of acute PE (with or without DVT) * Cohort 2: Clinical suspicion of acute DVT (without symptomatic PE) * Cohort 3: Incidentally diagnosed VTE

Contact & Investigator

Central Contact

Philipp S Wild, MD, MSc

✉ philipp.wild@unimedizin-mainz.de

📞 0049 6131 17 7163

Principal Investigator

Philipp S Wild, MD, MSc

PRINCIPAL INVESTIGATOR

University Medical Center of Johannes Gutenberg University Mainz, Germany

Frequently Asked Questions

Who can join the NCT02156401 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Venous Thromboembolism (VTE). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02156401 currently recruiting?

Yes, NCT02156401 is actively recruiting participants. Contact the research team at philipp.wild@unimedizin-mainz.de for enrollment information.

Where is the NCT02156401 trial being conducted?

This trial is being conducted at Mainz, Germany.

Who is sponsoring the NCT02156401 clinical trial?

NCT02156401 is sponsored by Johannes Gutenberg University Mainz. The principal investigator is Philipp S Wild, MD, MSc at University Medical Center of Johannes Gutenberg University Mainz, Germany. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology